Heterocyclic inhibitors of necroptosis
AssigneesThe Brigham and Women's Hospital, Inc., President and Fellows of Harvard College, Tufts University
InventorsGregory D. Cuny, Xin Teng, Junying Yuan, Alexei Degterev
Life of this patent
Estimating the term…
Abstract
The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
Claims10
A method of treating necrosis or necroptosis in a subject having a condition selected from stroke, myocardial infarction, organ ischemia, traumatic brain injury, liver disease, cancer chemo/radiation therapy-induced necrosis, acute necrotizing pancreatitis, or a neurodegenerative disease, said method comprising the step of administering a compound according to the following formula,
- wherein
- R1 is a lower alkyl group;
- R2 is selected from hydrogen and an electron withdrawing group;
- R3 is selected from hydrogen and an (S)-lower alkyl group;
- each of R4, R5, and R6 is independently selected from hydrogen, lower alkyl, halogen, amino, amido, alkoxy, and cyano;
- and
- each X1 and X2 is, independently, halogen;
- or any pharmaceutically acceptable salt thereof, or stereoisomer thereof.
A method of treating necrosis or necroptosis in a subject having a condition selected from organ ischemia, traumatic brain injury, liver disease, cancer chemo/radiation therapy-induced necrosis, acute necrotizing pancreatitis, or a neurodegenerative disease, said method comprising the step of administering a compound selected from the group consisting of:
- or any pharmaceutically acceptable salt thereof, or stereoisomer thereof,
- to said subject in a dosage sufficient to decrease necroptosis or said necrosis.
Dependencies are inferred from the claim text.